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Due to its essential roles in angiogenesis, Notch pathway has emerged as an attractive target for the treatment of pathologic 
angiogenesis. Although both activation and blockage of Notch signal can impede angiogenesis, activation of Notch signal may 
be more promising because it was shown that long-term Notch signal blockage resulted in vessel neoplasm. However, an in 
vivo deliverable Notch ligand with highly efficient Notch-activating capacity has not been developed. Among all the Notch 
ligands, Delta-like4 (Dll4) is specifically involved in angiogenesis. In this study, we generated a novel soluble Notch ligand 
hD4R, which consists of the Delta-Serrate-Lag-2 fragment of human Dll4 and an arginine-glycine-aspartate (RGD) motif tar-
geting endothelial cells (ECs). We demonstrated that hD4R could bind to ECs through its RGD motif and effectively triggered 
Notch signaling in ECs. Further, we confirmed that hD4R could suppress angiogenesis in vitro as manifested by network for-
mation assay and sprouting assay. More importantly, hD4R efficiently repressed neonatal retinal angiogenesis and la-
ser-induced choroidal neovascularization (CNV) as well in vivo. In conclusion, we have developed an in vivo deliverable 
Notch ligand hD4R, which suppresses angiogenesis both in vitro and in vivo, thus providing a new approach to tackle exces-
sive angiogenesis relevant disease such as CNV. 
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Angiogenesis is a critical process that involves the for-
mation of new blood vessels from preexisting vessels in 
response to proangiogenic factors such as VEGF and FGF 
generated upon tissue hypoxia [1]. Angiogenesis is normal-
ly under tight control during embryogenesis and adult tissue 
homeostasis, and its deregulation leads to numerous disease. 
Among them, age-related macular degeneration (AMD) is 
the leading cause of irreversible blindness in those people 
over 65 years of age [2]. The fast progressive ‘‘wet’’ form 
of AMD is featured by leaky excessive subretinal choroidal 
neovascularization (CNV), which leads to extravasations 
and hemorrhage into the photoreceptor cell layer, resulting 
in photoreceptor cell loss [2]. So far, several anti-VEGF-A 
antibodies have been under clinical trial to hamper the path-
ologic vascular outgrowth in AMD, however, the potential 
drug-resistance and high treatment burden call for the 
emergence of other novel drug candidates [2]. 
In metazoans, the evolutionarily conserved Notch path-
way functions as an essential cell-cell contact mechanism to 
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regulate numerous cell fate/lineage decisions during em-
bryogenesis, postnatal development, and adult tissue home-
ostasis [3]. There are five Notch ligands, namely Jagged1, 
Jagged2, Delta-like 1, 3, 4 in mammals. Among them, Del-
ta-like 4 (Dll4) is initially identified as an endothelium- 
specific Notch ligand, especially in tumor vasculature [4]. 
Ligand binding to Notch receptors induces the proteolytic 
release through the gamma-secretase-catalyzed proteolysis 
of the Notch intracellular domain (NICD), which translo-
cates into the nucleus and binds to the transcription factor 
CSL (C promoter-binding factor 1 [CBF-1]/suppressor of 
hairless [Su(H)]/Lin-12 and Glp-1 [LAG-1]). Association of 
NICD and CSL replaces a corepressor complex from CSL 
with a coactivator complex, and activates the transcription 
of downstream genes such as the Hes (Hairy and enhancer 
of split) family molecules Hey1, Hey2.  
Notch signaling pathway plays vital roles in sprouting 
angiogenesis involving endothelial tip and stalk cell speci-
fication and also vessel maturation characterized by mural 
cell differentiation and recruitment [3,5], thus it has been a 
promising target to handle pathological angiogenesis. It has 
been shown that both Notch activation and Notch blockade 
can repress angiogenesis [4]. However, compelling evi-
dence has demonstrated that long term inhibition of Notch 
pathway results in vessel neoplasm and other vital toxicity 
[6], strengthening the idea that activating Notch signal 
might be an alternative choice to restrain excessive angio-
genesis. Although a soluble Notch ligand is adequate for 
activating Notch signal in vitro, it might be insufficient to 
activate Notch ligand in vivo in that Notch activation relies 
on the endocytosis of the ligand in signal sending cells to 
expose the cleavage sites for γ-secretase [7]. To better in-
duce Notch signal in vivo, we have developed a fusion pro-
tein which is composed of the DSL domain of human Dll1 
(hDll1) and a nonapeptide (CRGDCGVRY) containing ar-
ginine-glycine-aspartate (RGD) [8]. RGD targets the integ-
rin αvβ3 which is expressed on endothelial cells (ECs) upon 
stimulation with angiogenic factors and it has been shown 
that the binding of RGD-containing molecular ligands with 
cell surface integrins triggers endocytosis [8,9]. We have 
demonstrated that hD1R could activate Notch signaling in 
both ECs and co-cultured human hematopoietic stem cells 
[10,11]. Because Dll4 is more specifically involved in an-
giogenesis [4], in this study, we extended our study to this 
Notch ligand. We demonstrated that hD4R can effectively 
trigger Notch signaling in ECs and inhibit both physiologi-
cal and pathological ocular angiogenesis in vivo, thus 
providing a novel approach for anti-angiogenic therapy.   
1  Materials and methods 
1.1  Expression of recombinant Trx-hD4R protein in  
E. coli 
The DSL domain of the hDll4 (NM_019074) cDNA frag-
ment was fused with a RGD motif and amplified by PCR 
with a human lymphocyte cDNA library as a template. The 
primers are listed in Table S1 in Supporting Information. 
The resultant gene fragments were then cloned into 
pET32a(+) between the EcoR I and Sal I sites to construct 
pET32a-hD4R. The plasmid was transformed into the     
E. coli BL21, and the Trx-hD4R protein was induced with 
0.5 mmol L1 isopropyl β-D-thiogalactopyranoside at 37°C 
for 12 h. The purification of Trx-hD4R protein was accom-
plished by using a Ni2+-NTA column (Invitrogen, USA).   
1.2  Cell culture 
Primary human umbilical vein endothelial cells (HUVECs) 
were maintained for 35 passages in an endothelial cell 
medium (ECM; ScienCell, USA) supplemented with 5% 
FBS and endothelial cell growth supplement (ECGS). The 
recombinant Trx-hD4R, Trx or a γ-secretase inhibitor (GSI; 
Alexis Biochemicals, USA) was used at the concentration 
of 1 μg mL1 or 25 μmol L1, respectively. For the cell ad-
hesion assay, wells of 96-well dishes were coated with 5 μg 
different recombinant proteins at 4°C overnight, and then 
seeded with 1×105 HUVECs in each well. In some cases A 
RGD peptide (CRGDCGVRY) or a DGR peptide 
(CDGRCGVRY; CL Bio-Scientific, Xi’an, China) was in-
cubated with cells for 5 min at the concentration of 0.5 mg 
mL1 before adding to the wells. After culturing for 10 min, 
adherent cells were stained with crystal violet, photo-
graphed and subjected to image analysis. 
1.3  Western blot 
Purified recombinant protein or total cell lysates were sepa-
rated by SDS-PAGE and subjected to Western blot analysis 
with a rabbit anti-S-tag antibody (Abcam, USA) or a rabbit 
anti-NICD antibody (Santa Cruz Biotechnology, USA) at 
4°C overnight, followed by an HRP-conjugated secondary 
anti-rabbit IgG antibody (Millipore, USA). Membranes 
were developed by using the enhanced chemiluminescence 
system (Clinx Science Instruments, Shanghai, China). 
1.4  Immunofluorescence 
Cultured cells were fixed by 4% paraformaldehyde (PFA) 
for 30 min at room temperature and blocked with 1% bo-
vine serum albumin (BSA) and 0.5% Triton X-100 in 
phosphate-buffered saline (PBS) for 2 h, then incubated at 
4°C overnight with the rabbit anti-S-tag or rabbit anti-NICD. 
After washing, cells were incubated with a Cy3-conjugated 
goat anti-rabbit IgG secondary antibody (Sigma, USA). For 
tissue staining, retina or choroid samples were fixed over-
night at 4°C with 4% PFA, blocked and permeabilized, then 
immunostained with FITC-labeled GSL I-isolectin B4 
(Vector Laboratories, USA) at 4°C overnight. Images were 
captured with a fluorescence or confocal microscope.  
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1.5  Quantitative reverse transcription (RT)-PCR 
Total RNA was isolated with a TRIzol reagent (Invitrogen, 
USA) according to the manufacturer’s instructions. cDNA 
was synthesized by a reverse transcription system (TaKaRa, 
Dalian, China). MRNA expression levels were quantified 
using a kit (SYBR Premix EX Taq, TaKaRa), detected by 
ABPRI ISM 7500 Real-Time PCR System. The PCR pri-
mers are listed in Table S1 in Supporting Information.  
1.6  Endothelial network formation assay 
The 48-well dishes were pre-coated by adding 200 L Mat-
rigel Basement Membrane Matrix (BD Biosciences, USA) 
and incubated at 37°C for 40 min. HUVECs were then 
seeded on the gel together with 1.25 μg mL1 Trx or 
Trx-hD4R, and incubated at 37°C for 6 h. Images were ob-
served and the branches and the length of the cell cords of 
the enclosed lumens were measured. 
1.7  Fibrin bead assay 
The microbeads carrying 400 cells per bead were embedded 
in the fibrinogen containing thrombin (0.625 U mL1), and 
then 0.5 mL of EGM-2 medium was added with lung fibro-
blasts as described earlier [10]. Trx or Trx-hD4R was added 
at the concentration of 0.5 μg/well every other day. Sprout-
ing was quantified by measuring the number and length of 
sprouts 4 days later.  
1.8  In vivo application of recombinant proteins 
Postnatal day 3 (P3) pups were intravitreally injected with 
Trx or Trx-hD4R (0.1 μg) and then subcutaneously injected 
with Trx or Trx-hD4R (5 μg) once a day for 4 d. Eyes were 
collected on P7 and fixed in 4% PFA at 4°C overnight, and 
stained as described previously [12]. All animal experi-
ments were approved by the Animal Experiment Admin-
istration Committee of the University. 
1.9  Laser-induced CNV assay 
Laser-induced CNV assay was performed as described [12]. 
C57BL/6J mice were anesthetized and the pupils were di-
lated. Six laser burns were performed at the 2-, 4-, 6-, 8-, 
10-, and 12-o’clock positions of the posterior pole around 
the optic nerve of both eyes. Mice were then injected 
through the tail vein with of 25 μg of Trx-hD4R or Trx on 
days 1, 3, and 5 after laser irradiation. Eyes were collected 
and stained on day 7.  
1.10  Statistics 
Statistical analysis was performed with the Image Pro Plus 
6.0 and Graph Pad Prism 5 software. Student’s t test was 
used for statistical analyses (unless otherwise specified). 
Data were expressed as mean±standard deviation (SD). 
P<0.05 was considered statistically significant. 
2  Results 
2.1  Cloning, expression and purification of the recom-
binant protein hD4R 
The recombinant hD4R contained amino acid 121–221 of 
human Notch ligand Dll4 (including the DSL domain re-
sponsible for Notch receptor binding) and a RGD motif 
targeting ECs (Figure S1A in Supporting Information). The 
333 bp cDNA fragment encoding the DSL domain of hDll4 
fused with the RGD-encoding sequence was amplified from 
a human lymphocyte cDNA library by PCR (Figure S1B in 
Supporting Information). The resulting fragment was sub-
cloned into prokaryotic expression vector pET32a(+) con-
taining the Trx-His-S tag, and recombinants were identified 
with enzyme digestion using Sal I and Bgl II, which gener-
ated fragments of 5809 and 424 bp as expected (Figure S1C 
in Supporting Information). To produce the recombinant 
proteins, E. coli BL21 was transformed with pET32a-hD4R 
or the control vector. Then the expression of the recombi-
nant proteins was induced with 0.5 mmol L1 isopropyl 
β-D-thiogalactoside (IPTG) for 12 h at 37°C. SDS-PAGE 
analysis of protein extracts of total bacteria, the superna-
tants or the precipitates revealed that the recombinant pro-
tein hD4R mainly existed in the precipitation fraction (Fig-
ure S1D in Supporting Information). The recombinant pro-
tein was then purified with Ni2+-NTA affinity chromatog-
raphy (Figure S1E in Supporting Information). We detected 
the presence of a specific band of about 33 kD by Western 
blot with the anti-S-tag antibody, consistent with the esti-
mated molecular weight (32.3 kD) of hD4R (Figure S1F in 
Supporting Information).  
2.2  hD4R could bind to ECs specifically 
To verify whether hD4R could bind to ECs, the capability 
of HUVECs to adhere to culture dishes pre-coated with 
hD4R or Trx was evaluated in a cell adhesion assay. Much 
more HUVECs were found to adhere to culture dishes 
pre-coated with hD4R than to dishes pre-coated with Trx 
(Figure 1A and B). Moreover, the adherence of HUVECs to 
the hD4R-coated dishes could be blocked by a synthetic 
RGD nonapeptide but not by a DGR nonapeptide (Figure 
1C and D). Then the capability of hD4R binding to ECs was 
further examined with an in vitro binding experiment fol-
lowed by detection with immunofluorescence analysis. 
HUVECs and lung fibroblasts were incubated with hD4R 
and then subjected to indirect immunofluorescent staining 
with an anti-S-tag antibody. The result showed that hD4R 
could bind to HUVECs more strongly than to lung fibro-
blasts (Figure 1E and F). These results verified that hD4R 
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Figure 1  hD4R could efficiently bind to ECs through the RGD motif. A, HUVECs were plated in wells pre-coated with Trx or hD4R. After incubation, 
adherent cells were stained with crystal violet and photographed. B, Area of stained crystal violet of each field was quantified and compared (n=6). C, HU-
VECs were incubated with synthetic DGR or RGD nonapeptide and then distributed into wells pre-coated with hD4R. After incubation, adherent cells were 
stained with crystal violet and photographed. D, Area of stained cells per field was measured and compared (n=6). E, HUVECs and lung fibroblasts were 
incubate with hD4R and then detected by the anti-S-tag antibody. F, The intensity of fluorescent signals per cell was quantified and compared (n=5). Bars 
represent mean ±SD; *, P<0.05; **, P<0.01; ***, P<0.001. 
could efficiently bind to ECs, most likely through the RGD 
motif.  
2.3  hD4R activated Notch signaling in ECs  
To evaluate whether hD4R could activate Notch signaling 
in ECs, hD4R- or Trx-treated HUVECs were subjected to 
immunofluorescence staining for the cleaved Notch1 inter-
cellular domain which is an indication of the activation of 
Notch signaling. Clearly, there were much more positive 
staining signals in the hD4R-treated HUVECs than in the 
control cells, which were largely abolished by the admin-
istration of GSI (Figure 2A and B). Consistently, in HU-
VECs incubated with hD4R, Western blot analysis dis-
played a significant increase in the level of NICD, which 
was mostly abrogated by GSI (Figure 2C). Furthermore, the 
mRNA level of Hey1, a major Notch downstream target in 
ECs, increased remarkably in hD4R-treated HUVECs (Fig-
ure 2D). In addition, hD4R-treated HUVECs displayed a 
significant increase in the expression of VEGFR1 and de-
crease in the expression of VEGFR3 (Figure 2D), in line 
with previous reports [13,14]. These results demonstrated 
that hD4R could effectively trigger Notch signaling in ECs, 
thus being a functional Notch ligand in vitro. 
2.4  hD4R inhibited angiogenesis in vitro 
We then employed in vitro assays to examine the effects of 
hD4R on lumen formation and angiogenic sprouting by ECs. 
Firstly, HUVECs were cultured in a Matrigel Basement 
Membrane Matrix in the presence of Trx or hD4R, and the 
formation of endothelial networks was compared by count-
ing network branches and branch length per field. Com-
pared with the control, hD4R-treated HUVECs displayed a 
smaller amount of branches and much shorter branch length 
in each field, indicating that hD4R remarkably inhibited 
HUVECs network formation (Figure 3A and B). Then, in a 
fibrin gel bead assay which mimicked the angiogenesis 
process in vivo, the sprouting capability of ECs could be 
evaluated by the numbers of sprouts on each bead and the 
length of each sprout. As shown in Figure 3C and D, there 
was a remarkable reduction in the number of sprouts per 
bead and a dramatic decrease in the sprout length in 
hD4R-treated HUVECs, compared with that of control 
HUVECs. The result indicated that hD4R could effectively 
suppress the sprouting and elongation of sprouting buds of 
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Figure 2  hD4R could efficiently trigger Notch signaling. A, hD4R activated Notch signaling in a GSI-dependent manner. HUVECs were incubated with 
Trx, Trx-hD4R or Trx-hD4R plus GSI. NICD level was determined by immunofluorescence staining using the anti-NICD antibody. B, The intensity of fluo-
rescent signals per cell was measured and compared (n=6). C, Western blot. HUVECs were treated as in A. Western blot analysis of NICD was performed by 
using the anti-NICD antibody, with β-actin as an internal control. The bands were quantified and compared (n=6). D, HUVECs were treated as in A. Then 
the cells were harvested and the expression of Hey1, VEGFR1, and VEGFR3 was detected by quantitative RT-PCR (n=9). Bars represent mean±SD; *, 
P<0.05; **, P<0.01.  
 
Figure 3  hD4R could suppress angiogenesis in vitro. A, HUVECs were cultured on the Matrigel Basement Membrane Matrix in the presence of Trx or 
hD4R. Cells were cultured for 6 h for the formation of cell networks, and photographed. B, The formation of the endothelial networks was quantified by 
counting the number and length of branches per field and compared (n=6). C, HUVECs were mixed with microbeads and cultured for 96 h for angiogenic 
sprouting in the presence of Trx or hD4R. D, The numbers of sprouts and the sprout length per bead were counted and compared (n=5). Bars represent mean 
±SD; *, P<0.05; **, P<0.01.  
ECs. Collectively, these data indicated that hD4R repressed 
angiogenesis in vitro. 
2.5  hD4R suppressed angiogenesis in vivo 
We next examined the effects of hD4R on neonatal retinal 
angiogenesis. The retinal surface angiogenesis begins on 
early postnatal (P1) stage in mice and spreads from the optic 
stalk to the retinal periphery via gradient vascular develop-
ment [12]. So pups were first intravitreally injected and then 
subcutaneously injected with Trx or hD4R once a day for  
4 d, and the angiogenic sprouting of retinal vasculature was 
examined on P7 by whole-mount retinal staining with iso-
lectin B4. The distal, middle, and proximal regions of the 
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retinal vascular bed were examined separately for changes 
in vascular density and branch points. Compared with the 
control, hD4R-treated mice displayed a less condensed ves-
sel network and a decrease in vascular loops in the distal, 
middle and proximal areas (Figure 4A and B). Furthermore, 
the fronts of sprouting have less tip cells (Figure 4C). These 
in vivo data demonstrated that hD4R suppressed physiolog-
ical angiogenesis.    
Laser coagulation of the mouse choroid in C57BL/6J 
mice induced rupture of Bruchs membrane and subsequent 
CNV, representing a well recognized animal model for 
“wet” AM [5]. To test whether local administration of 
hD4R could hinder the progression of CNV, adult 
C57BL/6J were injected with Trx or hD4R after laser pho-
tocoagulation on days 1, 3, and 5, then CNV was detected 
by staining sections of choroid-sclera complexes through 
the laser spots with isolectin B4. Compared with the con-
trols, a significant decrease in CNV area in mice treated 
with hD4R was documented (Figure 4D), which demon-
strated that hD4R could inhibit pathological ocular angio-
genesis such as CNV. Collectively, these data indicated that 
hD4R suppressed both physiological and pathological ocu-
lar angiogenesis.  
3  Discussion  
The role of Notch in sprouting angiogenesis has been well 
defined by accumulating evidence. In the absence of Notch 
signaling ECs continue to form sprouts in response to 
VEGF, resulting in extra sprouts, as has been documented 
in different model systems such as zebrafish embryos, 
mouse retina and xenograft tumors [3,15]. Enforced Notch 
signaling represses angiogenesis both in vitro and in vivo 
[4,5,15]. Thus, Notch pathway has been a promising target 
to interfere with to benefit angiogenesis-related disease. 
Results from a number of studies using either a Dll4-   
specific neutralizing antibody [16], a Notch1-specific an-
tagonistic antibody [17], a soluble Dll4 fusion protein [18], 
or a soluble Notch fusion protein have confirmed profound 
impact of Notch signaling on angiogenesis, especially in 
tumors [5]. These studies have tried to block Notch signals 
for intervening with excessive angiogenesis, but meets great 
challenge of long-term toxicity. Skin lesions with features 
of vascular neoplasms were observed in male rats after 8 
weeks of continuous anti-Dll4 exposure [6]. Goblet cell 
metaplasia and complete blockade of T cell development 
coupled with ectopic appearance of immature B cells in the 
thymus were the major on-target toxicities of inhibiting 
Notch signaling [19]. On the other hand, enforced Notch 
signal also represses angiogenesis by restraining the number 
of tip cells and hindering EC proliferation [15]. Moreover, 
enhanced Notch signal promotes the coverage of mural cells 
and enhances EC adhesion, contributing to the improvement 
of vessel perfusion and function [20,21]. Thus, activation of 
Notch signal seems to be more promising than blockage of 
Notch signal in preventing excessive angiogenesis, espe- 
cially for controlling neovascular AMD. 
 
 
Figure 4  hD4R could hamper angiogenesis in vivo. A and B, P3 pups were treated with Trx or hD4R. Then on P7, the retinas were stained with 
FITC-labeled GSL I-isolectin B4. The structures of the whole, distal, middle and proximal retinal vasculature were shown in (A). The numbers of enclosed 
capillary loops and vessel area were compared (B) (n=6). C and D, Tip cells at the angiogenic fronts were counted and compared (n=6). E and F, Repre-
sentative confocal images showing repression of CNV by hD4R compared with the Trx control. CNV area (μm2) was quantified by using the Image pro plus 
6.0 (n=16). Bars represent mean±SD; *, P<0.05; **, P<0.01.  
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The activation of Notch signaling is dependent on bind-
ing with ligands, a protein family composed of three Delta 
and two Jagged members in mammals [4]. Among them, 
Dll4 is endothelium-specific and mainly responsible for 
initiating and maintaining a stalk cell fate to restrict sprout-
ing angiogenesis by counteracting VEGF signal. The extra-
cellular domain of Dll4 is composed of a N-terminal signal 
peptide domain, a DSL domain and multiple EGF repeats, 
in which DSL domain is responsible for binding to Notch 
receptor and has been reported to be adequate for activating 
Notch signal [4]. Although the DSL domain of Notch ligand 
is sufficient to activate Notch signal in vitro, it might not be 
highly efficient in vivo in that efficient Notch activation 
depends on endocytosis of the ligand in signal sending cells.  
RGD is a well-known peptide binding to endothelial spe-
cific αvβ3 integrin and RGD targeted molecules could stim-
ulate endocytosis, which is required for Notch activation [8]. 
Based on these reasons, we choose to express a fusion pro-
tein containing the DSL domain of hDll4 and a RGD pep-
tide, which is soluble and can stimulate endocytosis after 
binding to ECs through the integrin. In this study, we doc-
umented that hD4R specifically binds to Notch receptors 
and efficiently activate Notch signaling as manifested by 
increased intracellular NICD level and up-regulated down-
stream gene expression. Furthermore, we demonstrated that 
this fusion protein could dramatically suppress the network 
formation capability and sprouting angiogenesis of HU-
VECs, indicating that it is functional in vitro. More im-
portantly and encouragingly, although it could only mildly 
repress neonatal retinal angiogenesis, it greatly hindered the 
laser-induced CNV in mice, making it a promising treat-
ment of vessel outgrowth-related decease such as AMD. All 
these data have demonstrated that this novel fusion protein 
could work as an efficient Notch ligand in vivo. In summary, 
we have developed a novel functional Notch ligand hD4R 
that is endothelial targeted and highly efficient in vivo, thus 
providing a novel approach for anti-angiogenesis therapy. 
However, critical pharmaceutical characteristics of this fu-
sion protein, including its half-life in vivo and short-term or 
long-term toxicity, need to be carefully investigated before 
it could be tested clinically.  
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